Why Weight-Loss Drugs Could Be Game-Changers for Your Investment Portfolio
Weight-loss drugs are transforming both health care and Wall Street, with leading manufacturers like Eli Lilly & Co. (LLY) ...
Pharmaceutical Technology2h
RFK Jr. trumps domestic manufacturing agenda Day 2 of confirmation hearings
During a Senate HELP Committee hearing, RFK Jr. stated that President Trump is dedicated to bringing drug manufacturing "back ...
Mastercard earnings set an upbeat tone for fintech stocks. These numbers stand out.
Among the highlights from Mastercard's report were a pickup in U.S. volumes and an encouraging outlook for the year Mastercard Inc. showed a pickup in U.S. spending volumes during January, in an ...
Chelsearecord.com4h
GLP-1 Weight-loss Drugs Should be Made Affordable for all Americans
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Are weight-loss drugs like gym memberships? The answer is worth billions
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.